Copyright
©2005 Baishideng Publishing Group Inc.
World J Gastroenterol. Nov 14, 2005; 11(42): 6607-6612
Published online Nov 14, 2005. doi: 10.3748/wjg.v11.i42.6607
Published online Nov 14, 2005. doi: 10.3748/wjg.v11.i42.6607
Table 6 Comparison of mean serum KL-6 level among different study sub-groups
| Egyptian | Japanese | |||||
| HCC (+) | HCC (-) | P | HCC (+) | HCC (-) | P | |
| Chronic liver disease1: | 576 (522) | 398 (185) | 0.001 | 510 (300) | 350 (147) | <0.001 |
| HCV-related | 558 (524) | 400 (172) | 0.008 | 356 (290) | 382 (209) | >0.2 |
| HBV-related | 778 (663) | 246 (72) | >0.2 | 877 (292) | 340 (163) | <0.001 |
| Non-viral | 729 (538) | 446 (309) | >0.2 | 2622 () | 357 (160) | – |
| Cirrhotics | 599 (586) | 406 (159) | 0.035 | 510 (350) | 374 (196) | 0.035 |
| Non-cirrhotics | 518 (325) | 398 (185) | 0.045 | 225 (73) | 349 (222) | <0.001 |
- Citation: Gad A, Tanaka E, Matsumoto A, Wahab MAE, Serwah AEH, Attia F, Ali K, Hassouba H, el-Deeb AER, Ichijyo T, Umemura T, Muto H, Yoshizawa K, Kiyosawa K. Assessment of KL-6 as a tumor marker in patients with hepatocellular carcinoma. World J Gastroenterol 2005; 11(42): 6607-6612
- URL: https://www.wjgnet.com/1007-9327/full/v11/i42/6607.htm
- DOI: https://dx.doi.org/10.3748/wjg.v11.i42.6607